sulfinpyrazone and Hyperlipoproteinemia Type IV
sulfinpyrazone has been researched along with Hyperlipoproteinemia Type IV in 1 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Hyperlipoproteinemia Type IV: A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits.
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Sommariva, D | 1 |
Scotti, L | 1 |
Baroni, L | 1 |
Beggi, P | 1 |
Fasoli, A | 1 |
Other Studies
1 other study available for sulfinpyrazone and Hyperlipoproteinemia Type IV
Article | Year |
---|---|
[Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
Topics: Adult; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipi | 1980 |